Newsletter
TRANSCEND May - Nov 2021
RENDEZVOUS Dr. Arvinder Singh CEO, Arth Diagnostics
Volume XVIII • Issue 2
NEWS Another big step towards Making in India Page 7
Page 2
RECOGNITION Best Healthcare Entrepreneur of the Year Page 4
RECOGNITION Nikhil Vazirani recognized among Top 40 young leaders in healthcare Page 4
Page 5 CSR COVID-relief efforts
CHAIRMAN’S MESSAGE
We will continue to develop new products to reduce the incidence of other diseases. We recently introduced India’s first and only indigenously manufactured HCV Gen4 Ag+Ab kit. To add to the portfolio of COVID testing solutions, our R&D team has developed the Rapid Test and is currently in the process of developing the neutralizing antibody ELISA tests. Besides this, the instruments are being upgraded for an enhanced customer experience. On this note, I would like to also add that the COVID-19 range has been adjudged the Tech Solution of the Year at The Economic Times Healthcare Awards 2021. On the manufacturing front, we continue to strengthen our prowess… the AMTZ Vizag facility has recently rolled out its first batch of Erba EM 200. Further, to meet the growing demand for a wide range of biochemistry tests across the country, we have increased production at the Mumbai facility. These small steps are another big leap towards Making in India! This year has been extra special and has helped us further our purpose… to make an impact that matters! In what is set to be the largest humanitarian relief effort in the history of our company, we continue to donate critical equipment to government institutes especially in smaller cities.
Dear Partners, It’s my pleasure to connect with you and express my gratitude to you for continuing to work selflessly to make the real difference!
Globally, the latest addition to our product portfolio, is EC 90 - the next generation electrolyte analyzer. Further, we have made encouraging progress with many new installations across different regions.
Undoubtedly, the last two years have been remarkable in many ways. For the nation, this has been a period of adaptation, flexibility and continued growth. It has given us more strength! I feel proud to be a part of the healthcare community and contribute to the health of the nation through various efforts. We have risen to the challenge with resilience, to not just survive, but emerge stronger!
Most importantly, I want to thank each of you for inspiring us and giving us a common purpose - to help Doctors take better care of patients and put the health of the nation first!
Now is the time to look forward, especially since it marks the beginning of India’s 75th year of Independence! Our government continues to strengthen the healthcare infrastructure in an effort towards nation-building. And on our part, we continue to manufacture in India, for an Atmanirbhar Bharat, free from imports!
Jai Hind!
Suresh Vazirani Founder Chairman Transasia-Erba International Group of Companies
1
RENDEZVOUS
Along the way, I developed interest in face aesthetics and clinical cosmetology and further explored the specialization. I have completed Post Graduate Diploma in Clinical Cosmetology from Germany and New York, Cosmetic Dermatology from Canada, Fellowship in Facial Aesthetics from Sweden and Masters in Cosmetic Gynecology from Germany and recently established Arth Skin and Fitness.
When the going gets tough… the tough get going!
A famous quote that has been brought to life by a common man who believes in creating his own destiny!
What led you to a career in pathology and to set up Arth Diagnostics? While I was pursuing my internship, I realized that due to my physical inability, I won’t be able to give my 100% in case of a medical emergency. Pathology thus seemed like a suitable choice. Another reason that motivated me to take up pathology was that, back then, it was an evolving branch with not many advanced technologies. As a result, there was a huge dependency on the pathologist’s analytical skills.
Dr. Arvinder Singh CEO, Arth Diagnostics, Udaipur Your life story is an inspiration for many others. Take us through your journey. I suffered from polio when I was 8 months old and it left me with an 80% physical inability of the lower limbs. During the frequent corrective surgeries, I was in close contact with doctors and got motivated to pursue MBBS. Belonging to a middle class family, I took up odd jobs to financially support my education. I developed a keen interest in Civil Services and cleared the initial rounds. However, owing to polio, I couldn’t get field postings. That’s when I decided to pursue MD Pathology, as it was the best suited branch for me.
Diagnostic Excellence Award by Health Minister of Rajasthan, Dr. Raghu Sharma (1st from right)
It was also the right time to set up Arth Diagnostics to offer a reliable testing facility to cater to South Rajasthan. Arth has grown thanks to the trust of the doctors and patients. Today, we don’t just offer pathology but also radiology services such as sonography, digital MRI, CT scan, etc.
In 1999, I established Amolak X-ray and Diagnostic Centre in Udaipur and in 2003, we collaborated with the Piramal group. I took over as the Rajasthan Business and Technical Head and received appreciation for my managerial skills. This led me to explore my interests in management studies and I cleared the CAT examination and got selected to IIM Indore. I completed MBA in 2009 and till date I am the only Doctor, who is a gold medalist at any of the IIMs. I received an offer for a package of Rs. 90 lakhs from London, the highest package of IIM that year, but I refused and opted to stay in India.
The pandemic has brought diagnostic testing into focus. How do you envision the future of the diagnostic industry in the next 3-5 years? Diagnostics forms the backbone of any medical intervention and can never go out of focus. Over the years, patients too have realized this. When I started practicing in 1999-2000, patients were concerned whether there was a need to undergo so many tests. Today, they enquire if they need to undergo comprehensive blood testing. Everyone today knows, that an RT-PCR is a confirmatory test for COVID-19. That is the paradigm shift - the pandemic has taken diagnostics to every home!
I continued to run my clinic and in 2011, we collaborated with Dr. Lal Pathlabs. I took over their operations in the capacity of Vice President for the next two years. In 2013, I decided to start Arth Diagnostics. Further, I also pursued LLB in 2017 and today I am a legal counselor for IMA, Udaipur Chapter. 2
RENDEZVOUS
machine and not the pathologist. I foresee this to be a concern area, dissuading students to pursue it as a specialization. It is thus important to showcase the analytical expertise that a pathologist adds to testing. While automation can take care of the accuracy, the man behind the instrument plays an important role for correct diagnosis. Clinicians today, look at gaining 360 degree insights from a test report.
Though I believe that this is a good time for the industry, I would also like to add that with the mushrooming of corporate hospitals and chain labs, standalone labs could face challenges in the future. They should explore the opportunity of affiliating with bigger labs or starting home services to thrive. Tell us about your association with Transasia and what according to you differentiates us from our competitors?
It is time to give pathology its due recognition! It is no more a behind-the-scene job and a pathologist is an integral part of the clinical team!
My association with Transasia started within three months of opening of Amolak Diagnostics. At that time, Udaipur was a primitive market and not many labs offered automation. I purchased a hematology analyzer from Transasia and became the first pathologist to offer CBC tests on a fully automated platform. I can never forget the assistance offered to me by Transasia for installing the instruments when I was setting up my lab. They made it look like a seamless process!
What advice do you have for aspiring pathologists setting up labs? In managerial terms I would like to say, that the Indian diagnostic industry today is like a red ocean with cut-throat competition. In order to survive and sustain, laboratories need to combine pathology services with radiology and offer total solutions. I have personally opted for this model and I am gaining well. The second strategy could be to opt for collection centres and home services. And last, there is a huge market in the interiors of our country. It is difficult to get qualified pathologists in tier II-IV towns. I will advise aspiring pathologists, to move away from the already saturated tier I markets and explore the option of tying up with a hospital in these areas.
Today, I also have Transasia’s biochemistry analyzer and there has been no change in their approach of putting CUSTOMERS FIRST. What I like most about Transasia is that they are a true Indian company working hand-in-hand with the pathologists for a healthier nation. This is evident from the quality, reliability and accuracy of their analyzers, that have a very less downtime. The positive approach, dependency and immediate response by the sales and service teams, leaves us with no scope for complaints!
Besides your varied professional interests, what do you like to do in your ‘me time’? I have a curious and inquisitive nature. I like to hone new skills and exploring new fields excites me! I have recently tried my hands at digital marketing and website designing. I am also an avid reader, and like to On target - Silver medal at enhance my knowledge the National Shooting Championship Tournament in the medical field.
How can pathology figure more prominently in medical education? With the advent of automation and AI, there is a perception that all the work is now done by the
I love playing chess in my free time. I also have interests in shooting and have won a silver medal at the National Shooting Championship Tournament, in the past. By heart, I am adventurous. I have climbed Ladakh’s highest mountain peak and became the first person with a physical inability to deep-dive in Maldives. Meditation is very close to my heart as it helps me gain more insights. I intermittently opt for Vipassana.
Dr. Arvinder Singh with Transasia's Erba H 360
3
RECOGNITION
While Mr. Vazirani has established Transasia as India’s Leading IVD Company, Mr. Nikhil Vazirani in the capacity of the CEO of the Erba-Transasia International Group of Companies, has his eyes set on making the group one among the top five companies worldwide!
Best Healthcare entrepreneur of the year award for Mr. Vazirani It’s a matter of great pride that Mr. Suresh Vazirani has been adjudged as the Best Healthcare Entrepreneur of the Year at the 11th Medgate Today India Healthcare Awards 2021. The award program recognizes doctors, medtech company leaders and hospital administrators who demonstrate extraordinary success and excellence in areas such as innovation, financial performance and personal commitment to their businesses and communities, especially through these challenging times.
And it’s a great honor for us that the vision and efforts of our young leader have been recognized by Medgate Today magazine in their special issue - Top 40 under 40 - Next Wave in Healthcare. Nikhil shares the platform with some of the most eminent names such as Adar Poonawalla, CEO, Serum Institute of India, Alisha Moopen, Dy. MD, Aster DM Healthcare, Dr. Sabine Kapasi, Strategy Lead at UN COVID response team, Dr. Kashipa Harit- Deputy Director, NABH, among others.
Mr. Vazirani was selected by an eminent panel of judges, all experts in their field. Winners were recognized at a special gala award function, held virtually.
Transasia wins Economic Times Healthcare Award 2021 for its COVID-19 testing solutions
“It is an honour to receive this award I share this achievement with my entire team and our channel partners, who have worked tirelessly to help Doctors perform their d u t i e s seamlessly, and build the resilience to operate successfully and sustainably” said Mr. Vazirani.
Right at the start of the pandemic, the R&D teams in India, UK and USA collaborated to fast-track the development of COVID testing solutions. In no time, we successfully introduced Made in India COVID-19 testing kits for diagnosis and sero-surveillance. At the recently concluded Economic Times Healthcare Awards 2021, these kits have been recognized as the Tech Solution of the Year. On receiving the award, Mr. Vazirani said, “It’s a great honor that our COVID-19 testing solutions have won this recognition. It’s our vision to offer high quality and affordable diagnostic solutions. It’s a matter of pride for us that these kits have gained acceptance by reputed institutes in India for their sensitivity, reliability and ease-of-use. We were among the first in India to introduce the ErbaLisa COVID-19 IgG kit. The Erba MDx Rt-PCR kit is highly sensitive to detect even in low viral load. Further with the introduction of the ErbaQik COVID-19 Rapid Antigen Test we are offering a complete portfolio.”
The MT India Healthcare Awards have been instilled by Medgate Today, one of the leading healthcare magazines in Asia. Recognizing the nex-gen in healthcare
Nikhil Vazirani
We thank our patrons for trusting our products and services and remain committed to contributing to the Health of the nation!
4
NEWS - COVID RELIEF EFFORTS
Critical equipments like BiPAP machines aid in providing external support for patients facing difficulty in breathing. Cell counters help in monitoring disease severity and the coagulation analyzer play a critical role in the estimation of D Dimer and other coagulation factors for monitoring blood clotting.
Aiding the state governments with critical equipment While India was at the peak of fighting the second wave, Transasia stepped up its efforts and pledged critical equipment for monitoring disease severity, to several beneficiaries through state health governments in Maharashtra, Delhi, TN, UP, Telangana, Karnataka, WB, Agartala, Assam and Sikkim.
Transasia donates critical equipment to several state governments Cell Coagulation analyzers machines 200 Counters 40 for D Dimer testing 200 BiPAP
Sikkim’s Health Minister Mr. M.K. Sharma (extreme R)
Shri Rajendra-Patil Yadravkar, Minister of State for Public Health, Maharashtra (1st from L)
Shri Ma Subramanian, MoHFW, TN (centre)
Shri Satyendar Kumar Jain (R), Minister of Health, Delhi
Dr. Raghu Sharma, MoHFW, Rajasthan (1st from L)
Dr. Veer Singh, Principal (1st from R) & Dr. Neeraj Gupta, HOD, TB & Chest Infections (2nd from R), JLN Medical College, Ajmer
Ms. Kanchan Verma, IAS, MD, UPMSCL, UP
Prof. Arvind Rajwanshi, Exec. Dir. & CEO & Mr. S.K. Singh, Dy. Dir, AIIMS, Raibaraeilly
Smt. K.S. Latha Kumari, IAS, MD, KSMSCL, Karnataka
Dr. Nagendrappa, Dist. Health Officer, Tumkur (1st from L)
Mr. D. C. Jagadeesha, Dy. Commissioner, Udipi (1st from L)
Dr. V. Rambabu Naik, GM, Diagnostics, TSMSIDC, Hyderabad
Mrs. Mahua Banerjee, IAS, MD (1st from R) & Debashis Ghosh, Mgr., Procurement (centre), WBMSCL
Erba Elite 580 donated to Command Army Hospital, Lucknow
Prof. Chinmoy Biswas, Dir. of Medical Education, Tripura
Dr. Achyut Baishya, Principal & Chief Supdt.(1st from L) & Dr. Sasanka Baruah, HOD, Urology (centre), Guwahati Medical College
Erba Elite 580 donated to Dr. Bhimrao Jadhav, Dean, RGMC Kalwa
ECL 105 donation to Dr. R.C. Thakur, Principal cum Dean, (1st from L), Shri Lal Bahadur Shastri Govt. Hospital, HP
5
NEWS - COVID RELIEF EFFORTS
Medicine donation to NGOs, government and mission hospitals
Transasia partners with AMTZ for Affordable Oxygen Concentrator Program
Lending support to the needy, Transasia donated over 5 lakh tablets towards the recovery of COVID-19 patients. These medicines have been identified as a part of India’s COVID-19 treatment protocol and are enabling in mitigating the widespread human impact of the pandemic. The procurement and distribution of the medicines have been executed by the Vazirani Foundation and closely co-ordinated by our field personnel across the country.
The second wave of the pandemic witnessed hospitals running out of oxygen as the country faced a severe shortage. In order to meet the acute deficit that was proving dear to save lives, Transasia’s Vazirani Foundation, partnered with AMTZ to provide COVID-19 patients easy access to oxygen. The Affordable Oxygen Concentrator Program was launched to enable home isolation patients to rent oxygen concentrators for just Rs 300-500 per day for a minimum period of five days. The initiative was inaugurated by Shri Nitin Gadkari, Hon’ble Minister for Road Transport & Highways and the Minister of MSME, Govt. of India and Shri Amitabh Kant, CEO, Niti Ayog in association with Atal Innovation Mission (AIM) and Uber, to ensure swift and safe delivery to the patient’s home. Speaking at inauguration ceremony, Shri Gadkari said, “Our goal is to overcome the pandemic and save as many lives as possible. AMTZ’s initiative to provide the concentrators at an affordable price combined with Uber’s extensive network will ensure swift and efficient delivery.”
Ramakrishna Mission, Mumbai
Shri. S. S. Jain Mahaveer Medical Relief Society, Secunderabad • 500 oxygen concentrators in 3 months • 30 cities • 100 patients benefitted Bookings can be done via the O2Home App, available on Google Playstore and Apple store.
Sevabharati Trust and Kle’s Oxygenated COVID Care Centre, Hubli
Shilpakriti Mahisadol, Purba Medinipur, West Bengal 6
NEWS
been possible without the channel partners. The efforts of the distributors were recognized through special awards.
Partnering to put India first Our business channel partners are an important pillar of Transasia’s legacy of offering quality and affordable diagnostic solutions. The well-knit network of 350+ distributors along with the on-ground team of 700+ sales and service experts, reach out the some of the remote interiors of the country, not catered to by any other company! And that is where our strength lies!
Another big step towards Making in India During the lockdown, Transasia had set-up its fifth and Asia’s largest IVD manufacturing facility at AMTZ, Vizag. We are proud to announce that it has recently rolled out the first batch of Erba EM 200, fully automated clinical chemistry analyzers. In the forthcoming months, the production will be scaled up to 50 units/month. This will further meet the growing demand for a wide range of biochemistry tests from laboratories across the country, and add to our existing installed base of 7500+ Erba EM 200 analyzers PAN India.
And each year, we come together for a common cause…to ideate and share insights on how we can together keep the health of India First…in all that we do!
The pandemic hasn’t deterred us from staying connected, and we recently concluded our Annual Distributor Meet, TRANSMEET 2021 on a virtual platform. Spread across three days, the event was hosted by Mr. Anup Kar, National Sales Manager- Channel Partners and attended by our sales team and country-wide distributors. The leadership team engaged in an enriching discussion on exciting new products and the road ahead. Expressing his views, Mr. Bhupendra Chowdhary, President, Sales and Marketing, said, “Engaging with our partners is an important step in engaging with end-customers. We expect growth of the company and in return growth of the partners in the year ahead.” Further, Mr. R.S. Subramanian, Vice President Product Management and Business Development added, “We look forward to introducing new products soon and the continued support of our channel partners.” Erba EM 200 being manufactured at Asia’s largest IVD manufacturing facility at AMTZ, Vizag
We are proud that all through the pandemic, Transasia has been able to offer uninterrupted services to our customers, and this woul not have 7
PRODUCT NEWS
“Transasia’s instruments have always stood the test of time for their efficiency and reliability. I am proud that at the BJ Medical College, Erba XL 640 has helped in providing seamless operations for the effective diagnosis and disease management for 1.5 mn patients. Thank you to the hospital management for their long lasting trust in us”, said Mr. Anil Jotwani, Sr. President, Transasia Bio-Medicals Ltd.
COMING SOON: ErbaQik COVID-19 Antigen Test For the last two years, since the start of the pandemic, the Transasia-Erba team has left no stone unturned to contribute to the fight! Be through the development of the diagnostic tests or catering to the customers through uninterrupted services. Right from the beginning, the R&D teams in India, USA and UK have collaborated to introduce the Erba COVID-19 IgG and IgM test kits and the Erba MDx COVID-19 RT-PCR kits. Offering high sensitivity and specificity, these kits have been well received by customers, in India as well as globally.
Fully Automated Biochemistry Analyzer
As a next step to offering comprehensive testing solutions for COVID-19, the team at Transasia has been working on developing the ErbaQik COVID-19 Antigen Test. The kit has already been approved by ICMR and will be available very soon. It will be manufactured at the AMTZ factory, Vizag - Asia’s largest manufacturing facility for COVID-19 testing solutions.
Trusted for their accuracy, Erba Ferritin kits and Erba XL-640 form an integral part of a scientific study on dengue Not limited to the monsoons, dengue has now become a year-round disease, with an increasing burden in India. Medical experts continue to research its implication on various blood parameters for early diagnosis and to limit its severity.
COVID-19 Ag Test
The International Journal of Medical Reviews and Case Reports, Europe recently published a white paper on a scientific study titled ‘Diagnosis Embattled: Correlation of Serum Ferritin and Lipid Profile with severity of dengue in pediatric population.’ The study was conducted under the guidance of Dr. Mohit Rojekar, HOD Biochemistry at Rajiv Gandhi Medical College and Hospital, Mumbai.
The conjugate pad in the kit is coated with SARS CoV-2 nucleocapsid antibody for highly accurate reporting. It offers an easy-to-use protocol and result interpretation in just 20 minutes.
We are proud that the Fully Automated Biochemistry Analyzer, Erba XL 640 and Erba Ferritin kits, were chosen to carry out the study, on account of the reliability and accuracy of reporting.
While RT-PCR continues to be the gold standard method for detection of COVID-19, rapid antigen tests are preferred for quick diagnosis, especially in low-cost settings. The ErbaQik COVID-19 Antigen Test will further aid in reaching out to these patients in remote areas.
BIOCHEMISTRY | ORIGINAL ARTICLE
DIAGNOSIS EMBATTLED - CORRELATION OF SERUM FERRITIN AND LIPID PROFILE WITH SEVERITY OF DENGUE IN PAEDIATRIC POPULATION ∗ Dept.
Erba XL 640 - a testament of long-standing quality and reliability
Mohit V Rojekar∗ , Vandana Kumavat∗∗ , Jayesh Panot∗∗ , Arati Adhe Rojekar and Poonam Lalla ,1
of Biochemistry, Rajiv Gandhi Medical College, Kalwa, Thane, India , ∗∗ Dept. of Paediatrics Rajiv Gandhi Medical College, Kalwa, Thane. India, Dept. of IVF, PD Hinduja National Hospital and Research Center,Mumbai, India, Garden Apartment, Opp Diamond Garden , Above Barista, Chembur
ABSTRACT Introduction Dengue is a highly prevalent mosquito-borne disease which requires serum ferritin and lipid profile testing to understand the severity of the infection. The iron and lipids are essential elements for the formation of viral organelles and the proliferation of DNGV. Hyperferritinaemia correlates with the severity of Dengue virus (DNGV) infection. Serum ferritin level is disproportionately high and indicates the increased risk of developing the complications. Hypolipidaemia is an independent predictor of the severity of dengue infection in critical patients. Due to unavailability of dengue treatment, there is an upsurge in the demand of prognostic biomarker for the DNGV infection. In dengue fever, serum ferritin is disproportionately raised compared to any bacterial or viral infection, and this elevated level substantiates with an increased risk of rising complications. Aim:To investigate the correlation of serum ferritin, platelets and lipid profile with disease severity and if these could serve as a predictive marker for progression to severe disease. Materials and Methods:This cross-sectional, observational study was conducted on 100 subjects (50 cases and 50 controls) in a tertiary care referral hospital in Western India. Complete blood count at the time of admission and 48 hours along with Ferritin, renal and liver function tests and lipid profile were performed on XL-640 Biochemistry FAA manufactured by Transasia Biomedicals, ERBA Mannheim. Tests to identify the normality of data distribution and tests of correlation were applied. Results: Platelet count (p=0.02), total cholesterol (p=0.04), LDL (p=0.04) were found to be decreased while ferritin (p<0.05) and TG (p<0.05) were found to be significantly increased in cases than in controls. In cases and controls, the correlation of HDL with VLDL was not found to be statistically significant Conclusion:The present study had shown that elevated serum ferritin levels done on admission or the diagnosis of the illness could predict the severity of dengue. Further research is needed to study the exact role of lipid profile in dengue.
We are happy to share, that recently, Erba XL-640 completed 14 years of non-stop service at the BJ Medical College & Hospital, Pune, a well-known 154 year old, 1500 bedded Govt. hospital. Since 2007, the fully automated biochemistry analyzer has been trusted for accurate reporting for 8 mn biochemistry tests and 1 mn electrolyte tests.
KEYWORDS Aedes aegypti, Severity, Lipid profile, Platelets, Paediatric dengue, mosquito borne
Introduction
Copyright © 2020 by the Bulgarian Association of Young Surgeons DOI:10.5455/IJMRCR.Serum-Ferritin-lipid-profile-dengue-pediatric First Received: September 9, 2020 Accepted: October 20, 2020 Associate Editor: Ivan Inkov (BG); 1 Garden Apartment, Opp Diamond Garden , Above Barista, Chembur drpoonam.lalla@gmail.com
Dengue is a highly prevalent mosquito-borne disease caused by Aedes aegypti mosquitoes that act as a vector for the transmission. Dengue is marked by symptoms like dengue hemorrhagic fever (DHF), dengue septic shock (DSS), skin rash, nausea, vomiting, abdominal pain and hepatosplenomegaly.[1,2] Due to the severity of the disease, it is highly important to diagnose dengue early and accurately. Serum ferritin and lipid profile tests are widely used for diagnosis and prognosis of the disease. [3,4]
Mohit V Rojekar et al./ International Journal of Medical Reviews and Case Reports (2021) 5(2):12-16
8
PRODUCT NEWS
Contributing to nation-building with our latest installations We are thankful to our customers for trusting us as a preferred partner of choice!
Installation of Erba XL-1000 at Indira Gandhi Medical College & Hospital (IGMC), Shimla
Erba Elite 580 installed at SGL Superspeciality Hospital, Jalandhar
Installation of Erba XL-1000 at AIIMS, Nagpur
Installation of Erba XL 640 at Tanjore Medical College, Thanjavur, Tamil Nadu Erba XL-1000 installed at Microbe Lab, Gurgaon
Erba XL 640 installed at Stanley Medical College, Chennai First Erba XL-1000 for Bhopal – installed at Gandhi Medical College
First Lisa XL installation at Coimbatore Medical College
Installation of Erba XL-1000 at Vijayanagar Institute of Medical Sciences (VIMS), Bellary
Erba Elite 580 and Erba EM 360 installed at Jumbo COVID facility, Mumbai
Erba-XL 1000 installed at Medical College, Datia, MP 9
INTRODUCTION ,ĞƉĂƟƟƐ ŝƐ Ă ĚŝƐĞĂƐ ŚĞƉĂƟƟƐ ǁĂƐ ĞƐƟŵĂƚĞ ϭϬй ŽĨ ƚƌĂŶƐĨƵƐĞĚ ŝŶĚ E E ŚĞƉĂƟƟƐ ĂŶĚ ĐĂ WŽƐƚ ŝŶĨĞĐƟŽŶ͕ , s ZE ƚŽ ϲ ŵŽŶƚŚƐ ƚŽ ĚĞǀĞůŽ ŚĂƉƉĞŶ ďĞĨŽƌĞ ĂŶƟďŽ
PRODUCT NEWS
Erba Lisa® HCV Gen4 Ag+Ab
ErbaLisa® HCV G ŽƌĞ͕ E^ϯ͕ E^ϰ ĂŶĚ E ĂŶƟŐĞŶ ĂŶĚ ĂŶƟͲ, s
India’s 1 indigenously developed 4 Gen ELISA Kit th
st
Committed to ATMA NIRBHAR BHARAT
PRINCIPLE OF THE TE dŚĞ ErbaLisa® HC ĚĞƚĞĐƟŽŶ ŽĨ , sĐ Ő ĂŶƟͲ, sĐ Ő ĂŶƟďŽĚŝĞ , s ĐŽƌĞ ĂŶƟŐĞŶ ĂŶĚ
/Ŷ ƚŚĞ ĂƐƐĂLJ ǁŚĞŶ ŚƵ ƐƚĂďůĞ ĐŽŵƉůĞdž ǁŝƚŚ ƚ ĂŶƟŐĞŶ ŝŶ ƚŚĞ ƐƉĞĐŝŵ ĂŶƟďŽĚŝĞƐ͘ ŌĞƌ ǁĂƐŚ ĐŽŶũƵŐĂƚĞ ŵŽůĞĐƵůĞƐ͘ ǁĞůůƐ ĂŶĚ ǁĞůůƐ ĐŽŶƚĂŝ
Window period reduced to less than 28 days
Sensitivity: 100%
9 ϭϬ 11 12 ϭϯ ϭϰ
Specificity: 99.67%
Detects HCV Core Antigen and Anti HCV Antibodies in human serum and plasma Use of monoclonal antibodies to HCVcAg and mixture of Recombinant HCV Ag – Core, NS3, NS4 and NS5
CONTENTS OF THE KI Sr. No. Rea 1 HC ŽĨ ƌ 2 Sam ϯ Ŷ ϰ Ŷ ϱ , 6 ƐƐ 7 HC 8 HC
150 mins
Assay time: 150 min
Col ^ƚŽ tĂ ůĂ Str Zip
/ƚĞŵƐ ϭ ƚŽ ϭϭ ƐŚŽƵůĚ ď
Adaptable on fully MATERIALS REQUIRE automated ELISA processor ϭ͘ ϱϬͲϭϬϬ ђů ŵŝĐƌŽƉ
Erba Lisa HCV Gen4 - Next Generation Testing Solution 10
Ϯ͘ ϯ͘ ϰ͘ ϱ͘ ϲ͘
ENQUIRE >/^ ŵŝĐƌŽƉůĂƚĞ >/^ ŵŝĐƌŽƉůĂƚĞ NOW ŝƐƉŽƐĂďůĞ ŐůŽǀĞ dŝŵĞƌ͘ DĞĂƐƵƌŝŶŐ ĐLJůŝŶĚ
STORAGE ϭ͘ dŚĞ Ŭŝƚ ƐŚŽƵůĚ ďĞ Ϯ͘ /ŵŵĞĚŝĂƚĞůLJ ĂŌĞ
WARNING AND PRECA ϭ͘ dŚĞ ƚĞƐƚ ƐŚŽƵůĚ ď Ϯ͘ &Žƌ in vitro ĚŝĂŐŶŽ
Ŷ͕ ǁŚŝĐŚ ŝƐ ƉƌŝŵĂƌŝůLJ Ă ƌĞƐƵůƚ ŽĨ ďůŽŽĚ ƚƌĂŶƐĨƵƐŝŽŶƐ͘ ĐĐŽƌĚŝŶŐ ƚŽ ƌĞƉŽƌƚƐ ƉƵďůŝƐŚĞĚ ƉƌŝŽƌ ƚŽ ϭϵϴϬ͕ ƚŚĞ ƌŝƐŬ ŽĨ ƉŽƐƚͲƚƌĂŶƐĨƵƐŝŽŶ SCIENTIFIC UPDATE ƉƉƌŽdžŝŵĂƚĞůLJ ϵϬй ŽĨ ƉŽƐƚͲƚƌĂŶƐĨƵƐŝŽŶ ŚĞƉĂƟƟƐ ďĞŝŶŐ ĐĂƵƐĞĚ ďLJ ƚŚĞ E E ŚĞƉĂƟƟƐ ĂŐĞŶƚ͘ KƚŚĞƌ ƌĞƉŽƌƚƐ ĞƐƟŵĂƚĞĚ ƚŚĂƚ ϱ ƚŽ ĂĐƵƚĞ E E ŚĞƉĂƟƟƐ͕ ǁŝƚŚ ϰϬй ƚŽ ϲϬй ƉƌŽŐƌĞƐƐŝŶŐ ƚŽ ďĞĐŽŵĞ ĐŚƌŽŶŝĐ
Ğ ŝŶĨĞĐƚĞĚ ŝŶĚŝǀŝĚƵĂů͘ Ƶƚ ĂŶƟďŽĚŝĞƐ ĂŐĂŝŶƐƚ ǀŝƌĂů ƉƌŽƚĞŝŶƐ ŵĂLJ ƚĂŬĞ ƵƉ Combined Antigen-Antibody Detection Assay: Ğ ŝŶĚŝǀŝĚƵĂů ŵĂLJ ƐƉƌĞĂĚ ƚŚĞ ĚŝƐĞĂƐĞ͘ ĞƚĞĐƟŽŶ ŽĨ , s ĐŽƌĞ ĂŶƟŐĞŶ ĐĂŶ Current Testing Strategy for HCV infection ŝŶŐ ƚŚĞ ǁŝŶĚŽǁ ƉĞƌŝŽĚ ŽĨ ŝŶĨĞĐƟŽŶ͘
ƚ Ŭŝƚ ŝƐ Ă ƚǁŽ ƐƚĞƉ ƐŽůŝĚ ƉŚĂƐĞ ĞŶnjLJŵĞ ŝŵŵƵŶŽĂƐƐĂLJ ĨŽƌ ƚŚĞ ƋƵĂůŝƚĂƟǀĞ ĞƐ ƉƌĞƐĞŶƚ ŝŶ ŚƵŵĂŶ ƐĞƌƵŵ ĂŶĚ ƉůĂƐŵĂ͘ dŚĞ Ŭŝƚ ƵƟůŝnjĞƐ ŵŽŶŽĐůŽŶĂů ŵďŝŶĂŶƚ ĂŶƟŐĞŶƐ ŽĨ , s ŝ͘Ğ͕͘ ŽƌĞ͕ E^ϯ͕ E^ϰ ĂŶĚ E^ϱ ĨŽƌ ĚĞƚĞĐƟŽŶ ŽĨ ƉĞĐƟǀĞůLJ͘
anti-HCV
Symptoms +/HCV RNA Titer
The development of technologies for identification ŵŽŶŽĐůŽŶĂů ĂŶƟďŽĚŝĞƐ ƚŽ , s ĐŽƌĞ ĂŶƟŐĞŶ ;, sĐ ŐͿ ĂŶĚ Ă ŵŝdžƚƵƌĞ ŽĨ of HCV infected patients has been a topic of ŶƐ ŽĨ ,ĞƉĂƟƟƐ ǀŝƌƵƐ ĂƐ last ĐŽĂƟŶŐ research for the threeŵĂƚĞƌŝĂůƐ decades. ĨŽƌ It is ĚĞƚĞĐƟŽŶ crucial to ŽĨ , s ĐŽƌĞ screen blood donors for HCV infection to avoid its spread. Furthermore, it is crucial to screen organ donors in liver transplant surgeries.
Serologic Pattern of Acute HCV Infection with Recovery
ALT
NORMAL 0
1
2
3 4 5 6 1 Months Time after Exposure
2 3 Years
4
ĂĚĚĞĚ ƚŽ ƚŚĞ ǁĞůů͕ ƚŚĞ ďŽƵŶĚ ĂŶƟŐĞŶ ƉƌĞƐĞŶƚ ŝŶ ƚŚĞ ǁĞůů ǁŝůů ĨŽƌŵ Ă Ref: www.cdc.gov ƉƌĞƐĞŶƚ ŝŶ ƚĞƐƚ Žƌ ƉŽƐŝƟǀĞ ĐŽŶƚƌŽů ƐƉĞĐŝŵĞŶ ǁŚŝůĞ ƚŚĞ ĨƌĞĞ , s ĐŽƌĞ Prevalence of HCV in India , sĐ Ő ĂŶƟďŽĚŝĞƐ ƉƌĞƐĞŶƚ ŝŶ ƚŚĞ ǁĞůů ĂŶĚ ĐŽŶũƵŐĂƚĞĚ ĂŶƟͲ, sĐ Ő ŵĂŶ /Ő' ;&ĐͿ ĂŶƟďŽĚŝĞƐ ĂƌĞ ĂĚĚĞĚ ƚŽ ƚŚĞ ǁĞůůƐ͘ KŶůLJ ƚŚĞ ďŽƵŶĚ ĂŶƟŐĞŶͲĂŶƟďŽĚLJ ĐŽŵƉůĞdž ƉƌĞƐĞŶƚ ŝŶ ƚŚĞ ǁĞůů ǁŝůů ƌĞĂĐƚ ǁŝƚŚ ƚŚĞ Hepatitis C is a disease caused by viral infection, ǁŝůů ƌĞŵŽǀĞ ƚŚĞ ƵŶďŽƵŶĚ ĐŽŶũƵŐĂƚĞ ŵŽůĞĐƵůĞƐ͘ ĚĚŝƟŽŶ ŽĨ ĐŽůŽƌ ƌĞĂŐĞŶƚ ǁŝůů ůĞĂĚ ƚŽ ĐŽůŽƌ ĚĞǀĞůŽƉŵĞŶƚ ŽŶůLJ ŝŶ ƉŽƐŝƟǀĞ ĐŽŶƚƌŽů which is primarily a result of blood transfusions. s ĂŶƟďŽĚŝĞƐ ŝŶ ƚĞƐƚ ƐƉĞĐŝŵĞŶ ƉƌĞƐĞŶƚ ŝŶ ƚŚĞ ƌĞƐƉĞĐƟǀĞ ǁĞůůƐ͘ Based on some regional level studies, it is estimated that in India, there are approximately 6-12 million people with Hepatitis C.
96 tests India is a signatory to the UN Resolution on Sustainable HCV core Antigen wells ʹ ƌĞĂŬĂǁĂLJ ŵŝĐƌŽǁĞůůƐ ĐŽĂƚĞĚ ǁŝƚŚ ĂŶƟͲ, sĐ Ő ĂŶƟďŽĚŝĞƐ ĂŶĚ Ă ŵŝdžƚƵƌĞ ϭ EŽ͘ Development Goals. In response to the call of the Ĩ , s ŽƌĞ͕ E^ϯ͕ E^ϰ ĂŶĚ E^ϱ WHO, the Ministry of Health and Family Welfare īĞƌ ǁŝƚŚ ƐĂůƚƐ ĂŶĚ ĚĞƚĞƌŐĞŶƚ ƚŽ ďĞ ƵƐĞĚ ĂƐ ĚŝůƵĞŶƚ ĨŽƌ ŽŶũƵŐĂƚĞ /͘ launched National Viral Hepatitis ϭϮ ŵů Control Program Beyond this, the screening of HCV in the general (NVHCP) on World Hepatitis Day (July ů ʹ ZĞĂĚLJ ƚŽ ƵƐĞ͕ ŝŶĂĐƟǀĂƚĞĚ ŶŽƌŵĂů ŚƵŵĂŶ ƐĞƌƵŵ ϭ ŵů28) of 2018. population is of paramount importance to control The aims of the program include: hepatitis associated illness including fibrosis, cirrhosis, ʹ ZĞĂĚLJ ƚŽ ƵƐĞ͕ ŝŶĂĐƟǀĂƚĞĚ ŚƵŵĂŶ ƐĞƌƵŵ ĐŽŶƚĂŝŶŝŶŐ ĂŶƟͲ, s Ϯyϭ ŵů and possibly hepatocellular carcinoma, because ƌŽů ʹ ZĞĂĚLJ ƚŽ ƵƐĞ͕ , s ŶƟŐĞŶ ϭ ŵůcountrywide • Combating hepatitis and achieve they are preventable. In many cases, it is crucial to elimination of hepatitis C by 2030,ϲ ŵů ƚŽ ƵƐĞ͕ ƉƌŽƚĞŝŶ ĐŽŶƚĂŝŶŝŶŐ ďƵīĞƌ ƚŽ ŝŶĐƌĞĂƐĞ ƐĞŶƐŝƟǀŝƚLJ ĂŶĚ ƐƉĞĐŝĮĐŝƚLJ ŽĨ ƚŚĞ ĐŽŶũƵŐĂƚĞ͘ detect HCV infection during the window period. X)ʹ ĐŽŶũƵŐĂƚĞĚ ĂŶƟͲ, sĐ Ő ĂŶƟďŽĚŝĞƐ Ϭ͘ϲϱ ŵů In recent years, a new technique for the detection of • Achieving significant reduction in the infected ĂĚLJ ƚŽ ƵƐĞ͕ ĐŽŶũƵŐĂƚĞĚ ĂŶƟ ŚƵŵĂŶ /Ő' ĂŶƟďŽĚŝĞƐ͘ ϲ ŵů associated the HCV core antigen (HCVcAg) in blood or plasma population, morbidity and mortality
samples has been commercialized. HCVcAg is a with hepatitis B and C, namely liver cirrhosis and ƵƐĞ͕ ϯ͕ϯ͕͛ϱ͕ϱ͛ͲdĞƚƌĂ ŵĞƚŚLJů ďĞŶnjŝĚŝŶĞ͕ ŝŵĞƚŚLJů ƐƵůĨŽdžŝĚĞ͕ ,ϮKϮ ϲ ŵů highly conserved and antigenic protein of the hepatocellular carcinoma, and ƚŽ ƵƐĞ͕ ƉŚŽƐƉŚŽƌŝĐ ĂĐŝĚ ϭϮ ŵů internal capsid. This structural protein is released ŶĐ͘Ϳ ʹ ƵīĞƌ ĐŽŶƚĂŝŶŝŶŐ ƐƵƌĨĂĐƚĂŶƚ͘ ŝůƵƚĞ ϭ͗ϮϬ ǁŝƚŚ ĚŝƐƟůůĞĚ ǁĂƚĞƌ ďĞĨŽƌĞ ƵƐĞ͘ and can be detected early, well before the antibodies • Reducing the risk, morbidity andϯϬ ŵů mortality due to against the virus, and throughout the complete course hepatitis A and E. ŝĚ ĞdžƉŽƐƵƌĞ ƚŽ ůŝŐŚƚ ĚƵƌŝŶŐ ŝŶĐƵďĂƟŽŶ ϭ EŽ͘ of the infection. This reduces the window period of ĂĐŬ ƐƚƌŝƉƐ ĨŽƌ ƐĞĂůŝŶŐ ƐƚƌŝƉƐ ĚƵƌŝŶŐ ŝŶĐƵďĂƟŽŶ ŝŶ ŽƌĚĞƌ ƚŽ ĂǀŽŝĚ ĞǀĂƉŽƌĂƟŽŶĂů ůŽƐƐ Ϯ EŽƐ͘ infection. HCV-cAg has been described as an active The key components of the program include ϭ EŽ͘ marker of infection, thus being an alternative to
HCV-RNA, with A1 evidence grading by the European Ɛƚ ŝƚĞŵƐ ŝ͘Ğ͘ ϭϮ ƚŽ ϭϰ ĐĂŶ ďĞ ƐƚŽƌĞĚ Ăƚ ƌŽŽŵ ƚĞŵƉĞƌĂƚƵƌĞ ;ϮϬͲϯϬΣ Ϳ͘ Association for the Study of the Liver.
• Prevention through awareness generation, immunization, blood and injection safety in healthcare settings, harm reduction for people who inject drugs and provision of safe drinking water, and hygiene and sanitary toilets;
However, after seroconversion, HCV RNA as well ϳ͘ ďƐŽƌďĞŶƚ ƉĂƉĞƌ͘ as HCV antigen become undetectable as a ϴ͘ ŝƐƉŽƐĂďůĞ ƟƉƐ͘ consequence of a progressive decline in viremia ϵ͘ tĂƐƚĞ ĚŝƐƉŽƐĂů ĐŽŶƚĂŝŶĞƌ͘ which couldϭϬ͘ ŝƐƟůůĞĚ ͬ ĚĞŝŽŶŝnjĞĚ ǁĂƚĞƌ͘ make NAT and HCV Ag specific • Diagnosis and treatment including screening of assays inefficient for the diagnosis of HCV infection. ϭϭ͘ ^ŽĚŝƵŵ ŚLJƉŽĐŚůŽƌŝƚĞ ƐŽůƵƟŽŶ ĨŽƌ ĚŝƐƉŽƐĂů ŽĨ ǁĂƐƚĞ͘ pregnant women in areas where institutional ϭϮ͘ ϯϳΣ ŝŶĐƵďĂƚŽƌ Hence, simultaneous detection of HCV core deliveries are <80% and free screening at all antigen and anti-HCV antibodies improves the levels of healthcare overtime, ensuring adherence early detection of HCV infection. through community/peer support and linkages to Z ͘ private sector and nonprofit organizations for Ɛ Ăƚ ϮͲϴΣ treatment;
ƟƉ͘
ĞƌƐŽŶŶĞů ŽŶůLJ͘
11
SCIENTIFIC UPDATE
developed HCV Gen 4 ELISA assay. ErbaLisa® HCV Gen4 Ag+Ab uses monoclonal antibodies to HCV core antigen (HCVcAg) and a mixture of Core, NS3, NS4 and NS5 recombinant proteins of Hepatitis C virus as coating materials for detection of HCV core antigen and anti-HCV antibodies.
• Establishment of systems for surveillance, monitoring and evaluation, and research; and • Training and capacity building of laboratory personnel and treatment and care providers Diagnosis of HCV infection
The ErbaLisa® HCV Gen4 Ag+Ab test kit is a two-step solid phase enzyme immunoassay for the qualitative detection of HCVcAg and anti-HCV antibodies present in human serum and plasma.
Currently, the diagnosis of HCV is at minimum a two-step process that involves screening for exposure to HCV using an indirect serological assay to detect HCV antibodies and confirmation of active infection using a nucleic acid test (NAT) to detect viral RNA in the plasma or serum (i.e. viral load).
Some of the key features include: • Window period reduced to less than 28 days
While these two tests are able to identify and diagnose patients with active HCV infection, they are only as successful as their availability allows. The HCV antibody test is relatively inexpensive with a quick turnaround time (TAT) and can be performed by most clinical laboratories, but a large number of patients who test positive for HCV antibodies are lost to follow-up and never receive a confirmatory HCV RNA test. The two-step diagnostic process is an onerous one for the patient, and the resultant loss of patients to follow-up is a significant obstacle in the continuum of care.
• Use of monoclonal antibodies to HCVcAg and mixture of Recombinant HCV Ag – Core, NS3, NS4 and NS5 • Assay time : 150 min • Sensitivity : 100% • Specificity : 99.67% • Adaptable on fully automated analyser
In addition to the time burden experienced by the patient, other challenges also factor into the low rate of confirmatory testing. NATs are performed by highly trained staff at specialized laboratories that have the capacity to run complex assays; an estimated 84% of people do not have access to these specialized laboratory facilities.
Advantages of combined Antigen Antibody test Immunoassays for combined detection of Antigen-Antibodies are more convenient, as they so not require specially trained laboratory personnel or special facilities; in fact, these assays can be performed on the same analyzer and at the same time as the HCV antibody test. Further, they are cost-effective, require smaller samples, have quicker TAT compared to RNA tests, and the test samples are more stable.
For those patients who do have access, the cost of the test itself is often prohibitive. The effect of these limitations is marked in low-income, resource-poor settings.
What does the future hold HCV core antigen – A promising alternative Since the first detection of the HCV core antigen in 1996, HCVcAg testing has come a long way. The affordability and simplicity of this test makes it a viable alternative in LMIC populations, where a sensitive qualitative assay that can readily identify those with active infection will go a long way toward containing the spread of HCV and initiating care for those who need it.
More affordable, less complex diagnostic testing has the potential to greatly improve access to care for people with chronic HCV in low- to middle-income (LMIC) areas and to help forge the way toward the elimination of HCV. A promising alternative to HCV viral load testing is HCV core antigen (HCVcAg) testing. Empowering Blood Banks with Next Generation Immunology Testing Transasia offers India’s first and only indigenously 12
INDUSTRY SUMMITS
Manish Airan, Vice President- Quality, Regulatory, Business Excellence & Digitalization, while sharing insights during the panel discussion on The Regulatory Landscape for Medical Devices and Diagnostics in India - Opportunities and Challenges
Sharing perspective: Lab medicine in the post COVID era The pandemic has brought seismic changes to the healthcare industry, diagnostics in particular. It has set the platform for many interesting discussions on the future of the industry. Sharing some snippets from our leadership team at the various forums:
Manish Airan VP - Quality Assurance, Regulatory, Business Excellence & Digitalization
“We are proud that all our Make in India products are listed on GeM platform and we are among the top 5 preferred diagnostic providers for reputed government institutes. Adoption of this digital platform has actively increased our direct reach in rural India, especially during the pandemic.”
“In India, where resources are limited, providing quality healthcare is a challenge. In my opinion, a well-structured QMS can help achieve quality in healthcare systems. To make the QMS more effective, it should be made more agile and resilient to the changing business needs. In order to improve the quality of healthcare product and services, it’s important to focus on certain processes for skill development of temporary workers, logistics and transport of products, supplier development programs and digitization of QMS documents to make them analysis friendly.”
L. B. Gautam GM, Government Business
LB Gautam, GM - Govt. Business, while sharing insights during the panel discussion on Role of GeM in procurement during COVID-19 13th CII Global Medtech Summit
Manish Airan, Vice President- Quality, Regulatory, Business Excellence & Digitalization, sharing insights during the panel discussion on Quality Management in Healthcare - The Pivotal Role
“Accessibility of quality healthcare is still a big challenge for the 1.3 bn Indians. India is the 4th largest market in Asia for medical devices but still there is an 80% import dependency. This challenge has been resolved by the regulatory bodies like CDSCO who have taken some great initiatives such as introducing MDR 2017 that has helped manufacturers to gain confidence to develop products in India and devise processes for regulatory approvals. To further encourage Make in India, state FDAs too need to streamline the approval processes.”
“The COVID-19 pandemic has brought lab medicine to the forefront, and the government has realized the role of clinical diagnostics in the healthcare value chain. Technology and 13
INDUSTRY SUMMITS
digitalization will continue to provide further boost to the sector. Transasia’s R&D centres in India, US and Europe continue to work on technologies that will offer affordable diagnostics to the 650 million population who still do not have access to quality diagnostics. The volume of diagnostic tests will see an accelerated growth of 20-22%. The Indian IVD industry is likely to witness a growth of 15% over the next 5 years,”
Dr. Manoj Chugh Vice President - R&D (Reagents)
physical delivery methods and digital elements like algorithms to enable integration. Switching from vertical to horizontal innovation is the key and for this, we need to bridge the gap between the isolated biological or physical sciences.” Suresh Vazirani Founder Chairman
India means Business: Cooperation Possibilities in Healthtech and Medical Devices - 8 October 2021
Suresh Vazirani, Founder Chairman and Managing Director while delivering the opening remarks
Panel Discussion: Changing Dynamics and New Opportunities - Making the Digital Leap in Healthcare & Medical Devices
“The COVID-19 pandemic has brought the strength of our science and technology to the forefront. There is a clear shift from the outmoded lab based technology to POCT or at-home testing. Burgeoning growth of vendors and tests offers opportunities for financial savings. However, on the flip side, it may also lead to lack of standardization across platforms. Manufacturers must be incentivized to innovate and produce. While it is important to keep pricing under control, to make diagnostics accessible and affordable to masses, a balance needs to be maintained, so that development and innovation can thrive.” Dr. Manoj Chugh, VP- R&D (Reagents) during the panel discussion on How IVD Industry transformed during COVID-19 pandemic
“The Digital Health Records program is a positive move towards creating digital health awareness. At Transasia, we are continually looking for ways to optimize how we work to improve patient care. We have developed customized plugin modules for labs to maintain digital health records and generate patient reports faster.”
7-8 October, 2021 Opening Remarks: Advancements in IVD Threats, Challenges and Opportunities “Developing, testing and deploying commercially successful IVD products require a multi-disciplinary approach. Manufacturing involves bringing together a number of complex components including biological materials,
- Mr. Suresh Vazirani
14
GLOBAL NEWS
Podcast 2.0: Let’s talk about Diagnostics!
Erba participates in EGY Health International Congress & Exhibition
The first podcast in the series Let’s talk about Diagnostics received an overwhelming response! The second episode is now out and focuses on infectious agents. The subject experts from the Erba team, discuss on the need for testing prior to blood donation to check for Transfusion Transmitted Infections (TTIs) and the guidelines laid done by WHO on blood safety and availability. They also raise concerns on the barriers to safe testing of blood such as irregular supply of testing kits.
The third edition of the EGY Health International Congress & Exhibition was held recently at Al Manara Convention Centre, Egypt. The Erba team participated in the conference and displayed its fully automated analyzers. The exhibition, the largest medical fair in Egypt, attracted more than 1000 attendees including medical professionals, medtech companies, hospitals, biomedical engineers from Egypt and the neighboring countries, including Arabian Gulf, the Middle East and Africa.
Further, they go on to discuss the different types of hepatitis infections and how ELISA testing for TTIs have evolved over the years. A podcast is a digital audio or a recording which is usually a part of a themed series. It can be downloaded and listened to, on various digital devices. The team will be hosting a series of podcasts at regular intervals comprising various topics from the different scientific disciplines. Participation in KBUD Kongre & Lab Expo 2021
The Erba team at the KBUD Congress & Lab Expo, Turkey
The Erba team is back to meeting customers at live events! At the recently concluded KBUD Congress & Lab Expo 2021, Erba showcased its state-of-the-art products such EC 90 (Critical Care analyzer), ECL 760 (Coagulation analyzer) and XL-640 (Biochemistry analyzer) among others.
Erba participates in Russian Diagnostic Summit After the series of lockdowns, the first Russian Diagnostic Summit was held in Moscow as a physical event. Erba showcased its products in the Biochemistry, Hematology, Coagulation and Urinalysis segments.
The KBUD Congress & Lab Expo 2021 and the 3rd Hereditary Metabolic Diseases Laboratory Symposium, organized by the Association of Clinical Biochemistry Specialists, in Antalya-Kemer, Turkey was attended by researchers and laboratory technology companies interested in biochemistry, molecular biology, immunology, hematology and laboratory medicine.
The conference was a combination of several major events on lab medicine and radiation diagnostics. Throughout the event, a series of scientific and educational sessions were held on the topics of laboratory, radiation and digitalization of diagnostic healthcare industries, among others.
The Erba team at the KBUD Congress & Lab Expo, Turkey
The Erba booth at the Russian Diagnostic Summit 15
GLOBAL NEWS
Growing our installation base Presenting some of our latest installations from across the globe
Erba XL 200 in Doti General Hospital in far west Nepal
Installation of EC 90 by Lab Solution Technologies Inc in Masbate Philippines Installation of Erba H 360 and Erba XL180 at Kathmandu
Erba H 560 in Olongapo, Philippines
Erba Elite 580 installation at Davos, Philippines
Installation of Erba XL 200 at Rizal, Philippines Installation of Erba XL 200 at We Care Hospital, Nepal
Elan 30s installation at the Greater Accra Regional Hospital, Ghana.
Laura XL at the Al-Basheer Hospital, Jordan
Erba XL 200 in Nepal
Erba Elite 580 at Mandaluyong Medical Hospital, Philippines
ERBA Diagnostics Mannheim GmbH
TRANSASIA BIO-MEDICALS LTD.
Transasia House, 8 Chandivali Studio Road, Andheri (E), Mumbai- 400 072 Tel.: (022) 4030 9000, Fax: (022) 2857 3030 Email: responses@transasia.co.in
Mallaustrasse 69-73 68219 Mannheim, Germany Tel.: (+49) 621 8799770 Fax: (+49) 621 8799688 Email: sales@erbamannheim.com
To Know More
73044 48818
responses@transasia.co.in
www.erbamannheim.com
16
Stay Connected: